These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354 [TBL] [Abstract][Full Text] [Related]
9. Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy. Lee KL; Benz SC; Hicks KC; Nguyen A; Gameiro SR; Palena C; Sanborn JZ; Su Z; Ordentlich P; Rohlin L; Lee JH; Rabizadeh S; Soon-Shiong P; Niazi K; Schlom J; Hamilton DH Cancer Immunol Res; 2019 Aug; 7(8):1359-1370. PubMed ID: 31292145 [TBL] [Abstract][Full Text] [Related]
10. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Redmond WL; Linch SN; Kasiewicz MJ Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278 [TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine. Abrams SI; Hodge JW; McLaughlin JP; Steinberg SM; Kantor JA; Schlom J J Immunother; 1997 Jan; 20(1):48-59. PubMed ID: 9101413 [TBL] [Abstract][Full Text] [Related]
12. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656 [TBL] [Abstract][Full Text] [Related]
13. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846 [No Abstract] [Full Text] [Related]
15. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10. Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349 [TBL] [Abstract][Full Text] [Related]
16. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo. Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377 [TBL] [Abstract][Full Text] [Related]
17. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity. Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502 [TBL] [Abstract][Full Text] [Related]
18. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118 [TBL] [Abstract][Full Text] [Related]
19. A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines. Donahue RN; Duncan BB; Fry TJ; Jones B; Bachovchin WW; Kiritsy CP; Lai JH; Wu W; Zhao P; Liu Y; Tsang KY; Hodge JW Vaccine; 2014 May; 32(26):3223-31. PubMed ID: 24731809 [TBL] [Abstract][Full Text] [Related]
20. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Saha A; Chatterjee SK Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]